Victory Capital Management
MACK

Victory Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Victory Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,352
Closed -$10K – 3762
2020
Q1 		$10K Buy
+4,352
New +$12.7K ﹤0.01% 3341
2019
Q4 		– Sell
-2,258
Closed -$10K – 3779
2019
Q3 		$10K Buy
+2,258
New +$11.3K ﹤0.01% 3288

Other funds holding MACK

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management's MACK Position: Q2 2020 in Review

Victory Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2020, closing a stake of 4,352 shares — an estimated $10K sold.

Victory Capital Management first reported a position in MACK in Q3 2019 and held it in 2 quarters. The position peaked at $10K in Q1 2020. 36 funds tracked by Wall St. Rank hold MACK as of Q2 2020.

  • Victory Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 4,352 Merrimack Pharmaceuticals, Inc. shares in Q2 2020, an estimated $10K.
  • Victory Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $10K in Q1 2020.
  • 36 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.